Nonspecific interstitial pneumonia: clinical associations and outcomes

详细信息    查看全文

• 作者：WenBin Xu ; Yi Xiao ; HongRui Liu ; MingWei Qin ; WenJie Zheng…
• 关键词：Non ; specific interstitial pneumonitis ; Connective tissue disease ; Prognosis
• 刊名：BMC Pulmonary Medicine
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：14
• 期：1
• 全文大小：547 KB
• 参考文献：This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 165: pp. 277-304 CrossRef
  1. Jacobs, RL, Andrews, CP (2003) Hypersensitivity pneumonia-nonspecific interstitial pneumonia/fibrosis histopathologic presentation: a study in diagnosis and long-term management. Ann Allergy Asthma Immunol 90: pp. 265-270 CrossRef
  2. Churg, A, Muller, NL, Flint, J, Wright, JL (2006) Chronic hypersensitivity pneumonitis. Am J Surg Pathol 30: pp. 201-208 CrossRef
  3. Rossi, SE, Erasmus, JJ, McAdams, HP, Sporn, TA, Goodman, PC (2000) Pulmonary drug toxicity: radiologic and pathologic manifestations. Radiographics 20: pp. 1245-1259 CrossRef
  4. de Lauretis, A, Veeraraghavan, S, Renzoni, E (2011) Review series: Aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ?. Chron Respir Dis 8: pp. 53-82
  5. Tafti, SF, Mokri, B, Mohammadi, F, Bakhshayesh-Karam, M, Emami, H, Masjedi, MR (2008) Comparison of clinicoradiologic manifestation of nonspecific interstitial pneumonia and usual interstitial pneumonia/idiopathic pulmonary fibrosis: a report from NRITLD. Ann Thorac Med 3: pp. 140-145 CrossRef
  6. Nagai, S, Handa, T, Tabuena, R, Kitaichi, M, Izumi, T (2004) Nonspecific interstitial pneumonia: a real clinical entity?. Clin Chest Med 25: pp. 705-715 CrossRef
  7. Saketkoo, LA, Matteson, EL, Brown, KK, Seibold, JR, Strand, V (2011) Developing disease activity and response criteria in connective tissue disease-related interstitial lung disease. J Rheumatol 38: pp. 1514-1518 CrossRef
  8. Shi, JH, Xu, WB, Liu, HR, Tian, XL, Feng, RE, Xu, ZJ, Zhu, YJ (2008) Clinico-pathological manifestations in interstitial lung diseases associated with polymyositis-dermatomyositis. Zhonghua Jie He He Hu Xi Za Zhi 31: pp. 250-254
  9. Ito, I, Nagai, S, Kitaichi, M, Nicholson, AG, Johkoh, T, Noma, S, Kim, DS, Handa, T, Izumi, T, Mishima, M (2005) Pulmonary manifestations of primary Sjogren's syndrome: a clinical, radiologic, and pathologic study. Am J Respir Crit Care Med 171: pp. 632-638 CrossRef
  10. Kim, DS, Yoo, B, Lee, JS, Kim, EK, Lim, CM, Lee, SD, Koh, Y, Kim, WS, Kim, WD, Colby, TV, Kitiaichi, ML (2002) The major histopathologic pattern of pulmonary fibrosis in scleroderma is nonspecific interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis 19: pp. 121-127
  11. Kinder, BW, Collard, HR, Koth, L, Daikh, DI, Wolters, PJ, Elicker, B, Jones, KD, King, TE (2007) Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?. Am J Respir Crit Care Med 176: pp. 691-697 CrossRef
  12. Romagnoli, M, Nannini, C, Piciucchi, S, Girelli, F, Gurioli, C, Casoni, G, Ravaglia, C, Tomassetti, S, Gurioli, C, Gavelli, G, Carloni, A, Dubini, A, Cantini, F, Chilosi, M, Poletti, V (2011) Idiopathic nonspecific interstitial pneumonia: an interstitial lung disease associated with autoimmune disorders?. Eur Respir J 38: pp. 384-391 CrossRef
  13. Park, IN, Jegal, Y, Kim, DS, Do, KH, Yoo, B, Shim, TS, Lim, CM, Lee, SD, Koh, Y, Kim, WS, Kim, WD, Jang, SJ, Kitaichi, M, Nicholson, AG, Colby, TV (2009) Clinical course and lung function change of idiopathic nonspecific interstitial pneumonia. Eur Respir J 33: pp. 68-76 CrossRef
  14. Travis, WD, Costabel, U, Hansell, DM, King, TE, Lynch, DA, Nicholson, AG, Ryerson, CJ, Ryu, JH, Selman, M, Wells, AU, Behr,
• 刊物主题：Pneumology/Respiratory System; Internal Medicine;
• 出版者：BioMed Central
• ISSN：1471-2466

文摘

Background Studies have shown that nonspecific interstitial pneumonitis (NSIP), even when initially diagnosed as an idiopathic form of the disease, might be associated with an autoimmune background that later reveals itself as an organ-specific or a systemic autoimmune disease. Methods NSIP patients were divided into three groups. The NSIP patients who met the criteria for having a systemic autoimmune disease (SAD) were defined as the systemic autoimmune disease-associated NSIP (SAD-NSIP) group. The NSIP patients who did not meet the criteria for a systemic autoimmune disease were defined as an antibody-positive group (i-NSIP-Ab + group) if their sera were positive for autoantibodies. The NSIP patients with negative serologic tests for auto-antibodies were defined as the antibody-negative group (i-NSIP-Ab- group). The clinical characteristics were analyzed and compared among the three groups. Results Ninety-seven NSIP patients were included. The mean age of the study population was 48 ± 11 years. The mean follow-up time was 54 ± 34 months. At the time of the surgical lung biopsies, 23/97 (23.7%) of the patients were classified as SAD-NSIP; 30/97 (30.9%) were in the i-NSIP-Ab + group; and 44/97 (45.4%) were in the i-NSIP-Ab- group. At the end of the follow-up period, three cases were diagnosed with polymyositis (one case from the i-NSIP-Ab + group, two cases from the i-NSIP-Ab- group), one with scleroderma (from the i-NSIP-Ab + group, scl-70 positive and skin biopsy) and another one with microscopic polyarteritis (from the i-NSIP-AB-group, p-ANCA and MPO positive, renal biopsy). Three cases in the i-NSIP-Ab- group were later found to be positive for autoantibodies. Due to these changes in classification, at the end of the follow-up period, the SAD-NSIP group consisted of 28/97 patients (28.9%), the i-NSIP-Ab + group of 31/97 (32.0%) and the i-NSIP-Ab- group of 38/97(39.1%). There were no significant differences in clinical manifestations, radiographic findings or pulmonary function tests among the three groups at the time of surgical lung biopsy or after reclassification after the follow-up period. SAD was an independent risk factor for the survival of the patients with NSIP after follow-up. Conclusion Follow-up is recommended because idiopathic NSIP may be the first manifestation of a systemic autoimmune disease.